IFNL3 and cryohydrocytosis: Either favorable or unfavorable alleles of both the rs12979860 and rs8099917 polymorphism reportedly have comparable SVRs or relapse rates in patients with CHC attaining an RVR during the combination therapy; therefore, the role of IL-28B gene polymorphism on VR in patients attaining RVR may be limited (32-35).